chrisvoncsefalvay/vaers-outcomes huggingface dataset:
A gentleman called at around 11:30  this morning asking if he should get his second scheduled dose of Moderna tomorrow. He said he received the Pfizer dose over 8 weeks ago from a drive up clinic and was having a hard time finding the Pfizer second dose. He received the Moderna IMZ from me at store 1689 on 4-13-21. His Moderna IMZ was scheduled online from him. He filled out online and checked that he did not receive any other vaccines in the last 4 weeks. I had now knowledge that the patient had received the Pfizer as his first dose.   We checked and he actually received the Pfizer IMZ on 3-27-21. I called Moderna and they stated that if patients cannot find the second shot from the same company they can receive another company's MRNA imz. I also spoke to, she said CDC now states that patients can receive another MRNA, different from the patient's first imz.   I did ask the patient if this was his first shot. I went over the side effects for Moderna. We scheduled his second shot for tomorrow morning not knowing until today that he already had the Pfizer imz.   I called the patient tonight around 8:15 pm to inform him that according to the CDC he is finished with his COVID imz now and I cancelled his second Moderna imz.   The patient was fine
- In the early morning of 4/14/21 Pt called Kaiser help line complaining of cold hands/ feet, restlessness, pallor, R arm pain.   - Telephone visit 4/14/21 complained of chills, nausea, vomiting, abdominal cramping, diarrhea. Fluids and rest recommended.   - 4/15/21 presented to Kaiser with chest pain, shortness of breath, abdominal pain.  Diagnosed with late presentation of acute coronary syndrome / anterior ST elevation MI.  Echo with low EF < 25%, LV apical thrombus - 4/16/21 heart catheterization showed 100% occlusion of LAD treated with PCI / DES x 2, IABP.  Endotracheal intubation for respiratory failure.
Fussiness and fever (102) onset the evening of vaccine (Wed 1/16) and continued through Monday evening (1/21). Treated with infants MOTRIN and baths to help bring temp down and make Patient comfortable.
He was wearing many layers of clothes due to working in a cold environment prior to receiving vaccine. He was also sweating a lot. About 5 minutes after he was vaccinated, he began to drift in and out of consciousness. His blood pressure was high (165 systolic), but glucose was normal. EMS was called and it was determined to be related to blood pressure and a reaction due to the Pfizer Covid vaccine. Patient was released from hospital.
Patient describes extreme weakness and disorientation to time, describing the event as "losing one whole day"
Onset of polyarthralgia malaise within 24 hours of vaccine administration. Duration of symptoms about 10 days, resolved with oral corticosteroid administration.
Severe local inflammation and getting worse over time from PNEUMOVAX 23. MD prescribed Doxycycline 100 BID x 10d.
Patient approximately 1 week after vaccine, pt had 1 week of fevers from 101-104.  He was diagnosed with strep, treated with abx and had continued fever for 3 days.  Pt then had 5 days of fevers with massive cervical adenopathy 2 weeks later, that was not treated with antibiotics.
Information has been received from a registered nurse RN concerning her adult daughter who was vaccinated with the first dose of varicella virus vaccine live. The RN reported hat her daughter developed a rash about one month after being vaccinated. Unspecified medical attention was sought. At the time of this report, the outcome was unknown. Additional information has been requested.
We were notified by the state health department that he is believed to have received 3 doses of the covid shot, at our facility on 7/16 and 6/25 as well as an earlier shot on 4/17 per the state immunization registry. We have called the patient numerous times and he has not returned our calls so it is unknown if he experienced any adverse effects.
Had 1st dose Moderna on 12/29/2020. Had 2nd dose Moderna on 01/26/21 and had booster dose on 10/28/21.  Tested positive for Covid on 01/19/2022. Symptoms included fatigue, stuffy nose , cough , low grade temp and muscle aches
Initial misuse report received from a healthcare professional on 03 January 2014. A patient had received a third dose of ACTHIB and DAPTACEL on 19 October 2013 and forth dose on 2 January 2014. It's an inappropriate schedule of vaccine administered. No adverse event was reported. List of documents held by sender: none.
NERVE PAIN; INTENSE HEAT IN BACK AND BACK HOT TO TOUCH; COULD NOT SLEEP; COULD NOT BEND FINGERS ON SIDE RECEIVED INJECTION; HEART RACING IN HEAD AND EARS INTENSELY; ARM SWOLLEN; LEG PAIN ,SEVERE PAIN WHOLE ARM AND INTENSE PAIN FROM LEGS UP HER BACK; ARM WAS NUMB; UPPER ARM HARD TO THE TOUCH AND PAIN IN BICEPS AND TRICEPS; This spontaneous report received from a patient concerned a 35 year old female. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 207A21A,expiry: 21-SEP-2021) dose was not reported, administered on 28-JUL-2021 10:00 for prophylactic vaccination. Concomitant medications included ibuprofen for leg and back pain.  On 28-JUL-2021, the patient experienced could not sleep. On 28-JUL-2021, the patient experienced could not bend fingers on side received injection. On 28-JUL-2021, the patient experienced heart racing in head and ears intensely. On 28-JUL-2021, the patient experienced arm swollen. On 28-JUL-2021, the patient experienced leg pain, severe pain whole arm and intense pain from legs up her back. On 28-JUL-2021, the patient experienced arm was numb. On 28-JUL-2021, the patient experienced upper arm hard to the touch and pain in biceps and triceps. On 29-JUL-2021, the patient experienced nerve pain. On 29-JUL-2021, the patient experienced intense heat in back and back hot to touch. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from nerve pain, and intense heat in back and back hot to touch on 01-AUG-2021, could not sleep, and heart racing in head and ears intensely on 31-JUL-2021, could not bend fingers on side received injection on 02-AUG-2021, and arm swollen on 20-AUG-2021, was recovering from arm was numb, and the outcome of upper arm hard to the touch and pain in biceps and triceps and leg pain ,severe pain whole arm and intense pain from legs up her back was not reported. This report was non-serious.
Shortness of breath, mild naseau, consistent bathroom urgency (not necessarily going), diarrhea when I can go to the bathroom.
Information has been received from a health professional concerning an 18 year old male, with no medical history or known drug allergies, who on 06/12/2001 was vaccinated with one dose of hep b vaccine recombinant. Concomitant therapy that day included one dose of hep a vaccine and one dose of meningococcal polysaccharide vaccine. On 06/14/2001 lab results revealed a bilirubin of 2.94 (normal range 0-1). The pt sought unspecified medical attention. Additional info has been requested.
High fever, vomiting. Diarrhea. Shakey, staggering.
going to throw up; dizziness; This is a spontaneous report from a contactable consumer from a Pfizer sponsored -program, Pfizer First Connect. A 42-year-old male patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EK9231), intramuscular on 22Dec2020 15:15 at a single dose to prevent COVID. Medical history included retinal blood clot in his retina which was why he was tested for RA, and Meniere's disease for which he was asked to try meclizine which was for inner ear but he did not start taking meclizine, and six years ago, they did blood work and he was told he may have rheumatoid arthritis (RA) or he may have markers for RA but he has had no further issues and does not take any medication for this. The patient's concomitant medications were not reported. The patient experienced dizziness on 06Jan2021. The dizziness was increasing and he felt it most of the time. On 07Jan2021, he started feeling swimmy headed and he left work on 11Jan2021 since he was told he looked horrible. He never leaves work. He went to the clinic on the 11th since he felt like he was dizzy and going to throw up. The next day he did not feel better. The outcome of the events was not recovered.
9/27/21: presented to the ER today for further evaluation of dyspnea, cough, and severe fatigue. COVID-19 Pneumonia,  Hypoxemia, Sx onset: 9/19 (chills only)  - COVID + on: 9/27  - Vaccination status: fully vaccinated  - Current sx: dyspnea, chills, fevers (Tmax 39.3 in ER), cough, increased trach secretions  - Current O2 requirement: 6L via trach
Numb arm from shoulder to elbow; Migraine; Fever; Neck pain; Anxiety; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  An 11-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 22May2022 at 15:45 as dose 3 (booster), single (Lot number: FL8095) at the age of 11 years, in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. Vaccination history included: BNT162b2 (DOSE 2, SINGLE, Batch/Lot No: FK5127, Location of injection: Left arm, Vaccine Administration Time: 11:00), administration date: 11Dec2021, when the patient was 10-year-old, for COVID-19 Immunization; BNT162b2 (DOSE 1, SINGLE, Batch/Lot No: FK5127, Location of injection: Left arm, Vaccine Administration Time: 10:30), administration date: 20Nov2021, when the patient was 10-year-old, for COVID-19 Immunization. The following information was reported: ANXIETY (non-serious) with onset 23May2022 at 12:30, outcome "not recovered"; PYREXIA (non-serious) with onset 23May2022 at 12:30, outcome "not recovered", described as "Fever"; MIGRAINE (non-serious) with onset 23May2022 at 12:30, outcome "not recovered"; NECK PAIN (non-serious) with onset 23May2022 at 12:30, outcome "not recovered"; HYPOAESTHESIA (non-serious) with onset 23May2022 at 12:30, outcome "not recovered", described as "Numb arm from shoulder to elbow". Therapeutic measures were taken as a result of hypoaesthesia, migraine, pyrexia, neck pain, anxiety. Additional information: The patient received at home symptom care. The patient had no COVID prior vaccination and no COVID testing was done post vaccination. The patient had no known allergies.
The Patient received the Pfizer-BioNTech COVID-19 Vaccine first dose but tested positive for covid 2 days after; The Patient received the Pfizer-BioNTech COVID-19 Vaccine first dose but tested positive for covid 2 days after; This is a spontaneous report from a contactable consumer. This consumer reported for her 76-year-old mother who received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) at single dose for COVID-19 immunisation. Relevant history and concomitant drugs were unknown. The patient was tested positive for COVID 2 days after the vaccination. Outcome of the event was unknown.   The information on the LOT/Batch number has been requested.
This spontaneous report as received from a licensed practical nurse refers to a patient of unknown age and unknown gender. The patient pertinent medical history was not reported. On 09-MAY-2014, the patient was vaccinated with PROQUAD (Merck) (dose strength and route was not reported) (lot # J014235 and expiry date: 07-MAY-2015, reported as 17-MAY-2015) which was improperly stored. Primary reporter was reporting excursion of 6 F since 01-JUN-2013 (confirmed date) affecting PROQUAD (Merck), nurse also reported that products were not stored in an overall average support range of -58 degree F and 5 degree F. No adverse effects reported. No product quality complaint (PQC) was reported for PROQUAD (Merck). This is one of the several reports from the same reporter. Additional information has been requested.
ache and pain in left thumb pad/Pain radiated up to left deltoid muscle; ache and pain in left thumb pad; Pain radiated up to left deltoid muscle; This is a spontaneous report received from contactable reporter(s) (Nurse). The reporter is the patient.  A 68-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 29Sep2022 at 14:15 as dose 4 (booster), single (Lot number: GJ2524) at the age of 68 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "HBP (controlled)" (unspecified if ongoing); "high cholesterol (moderate)" (unspecified if ongoing); "increased eye pressure" (unspecified if ongoing); "hx migraines" (unspecified if ongoing); "sciatica" (unspecified if ongoing). Concomitant medication(s) included: ATORVASTATIN; LISINOPRIL; ROCKLATAN; VITAMIN D3. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTURER UNKNOWN), for Covid-19 Immunization; Covid-19 vaccine (DOSE 2; MANUFACTURER UNKNOWN), for Covid-19 Immunization; Covid-19 vaccine (DOSE 3; MANUFACTURER UNKNOWN), for Covid-19 Immunization.  The following information was reported: MYALGIA (non-serious) with onset 20Oct2022, outcome "not recovered", described as "Pain radiated up to left deltoid muscle"; PAIN IN EXTREMITY (non-serious) with onset 20Oct2022, outcome "not recovered", described as "ache and pain in left thumb pad"; PAIN (non-serious) with onset 20Oct2022, outcome "not recovered", described as "ache and pain in left thumb pad/Pain radiated up to left deltoid muscle". The events "ache and pain in left thumb pad/pain radiated up to left deltoid muscle", "ache and pain in left thumb pad" and "pain radiated up to left deltoid muscle" required physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of pain, pain in extremity, myalgia.  Additional information: In late Oct2022 the patient began experiencing ache and pain in left thumb pad; more severe at night and occasionally during the day. Severe pain when pressed left thumb pad using right thumb and index fingers to press. Pain radiated up to left deltoid muscle. The patient had Chiropractor ordered an x-ray of left thumb, arm. No covid prior vaccination and the patient had tested covid post vaccination. The patient received Anti-viral product for COVID 19 Treatment start date: 01Dec2022 and stop date: 06Dec2022. No other vaccine in four weeks. No known allergies.
This case was reported by a other health professional via call center representative and described the occurrence of night sweat in a 58-year-old male patient who received SHINGRIX (batch number 957J3, expiry date 15th November 2020) for prophylaxis. On 4th September 2018, the patient received the 1st dose of SHINGRIX. On 4th September 2018, unknown after receiving SHINGRIX, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On 5th September 2018, the patient experienced night sweat, fever, chills and unwell. In September 2018, the patient experienced headache, general body pain and sweating. On an unknown date, the outcome of the night sweat and fever were recovering/resolving and the outcome of the chills, general body pain and unwell were not recovered/not resolved and the outcome of the headache, sweating, inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown. It was unknown if the reporter considered the night sweat, fever, chills, headache, general body pain, unwell and sweating to be related to SHINGRIX. Additional details were provided as follows: The reporter stated that the patient had only received the adjuvant of the SHINGRIX vaccine, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The patient said that he experienced night sweating, chills and a low grade fever the next day after receiving the vaccine. After 3 days, the patient still had the same symptoms from the injection including body ache, headache and sweating. The patient called the office back on 10th September 2018. He said that after 3 days, the patient still had the same symptoms from the injection including body ache, headache and sweating. The patient was still unwell that day, but it was the first day he started to feel better after the vaccination. The patient called the office back on the date of reporting, he went through some of the same side effects again with chills, body aches and pain.
Patient  had not started primary series with Monovalent mRNA and was given a Bivalent dose as the 1st dose.
During the night of 01/12/10; 01/13/10; and 01/14/10 patient vomited each night.  No fever was present.  Around 12:30 pm on 01/15/10 patient had seizure.  Again no fever was present.  She was taken by ambulence to the ER, where lab work was found to appear 'normal.'  No other cause for seizure was found.
This client felt faint with in 15 minutes of receiving TT, had to lye down. Ambulance phoned and monitored client.
Patient has c/o low grade fever, joint and muscle aches. Body aches all over.
Arm hot swollen, red area size of 2 dollar bills. 2 hrs after rec. vac. painful. Dr Rx Benadryl (OTC) 2 tablets PO. Now, 2 tabs 6 hrs later, Keflex 500mg QID x 7 D. #2B, no RF. Appt with doctor on 12-20-07. Doctor continue Benadryl x 2 days if not better 12-21-07. Rx Cipro 250mg BID x 7 d.
STABILITY DATA SUPPORTS THE USE OF THE VACCINE THOUGH OCT19.  THE VACCINE WAS REPORTED EXPRIRED ON SEP 30.  REVACCINATION WAS NOT INDICATED
Low grade fever , malaise, fatigue, nausea, swollen lymphnodes in collarbone area, swollen arm at injection site. Rash at injection site, headache , chills , body and joint ace and pain
Vaccine was initially stored in the refrigerator on 11-Jan-2022, expired on 05-May-2022 and administered on 11-May-2022; administered expired moderna vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (administered expired moderna vaccine) and PRODUCT STORAGE ERROR (Vaccine was initially stored in the refrigerator on 11-Jan-2022, expired on 05-May-2022 and administered on 11-May-2022) in an 87-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 084J21A, 014M20A and 012M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 07-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-May-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-May-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (administered expired moderna vaccine). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine was initially stored in the refrigerator on 11-Jan-2022, expired on 05-May-2022 and administered on 11-May-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (administered expired moderna vaccine) and PRODUCT STORAGE ERROR (Vaccine was initially stored in the refrigerator on 11-Jan-2022, expired on 05-May-2022 and administered on 11-May-2022) outcome was unknown.      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. The pharmacist identified an additional issue that staff were not dating the boxes of vaccine when placing them in the fridge for storage. This lot number (084J21A) was received and placed in the fridge on 11-Jan-2022 which meant that all doses administered more than 30 days after 11-Jan-2022.  Date the vial was initially stored in the refrigerator was 11-Jan-2022. The vial did not undergo any temperature excursions. Patients not had reported any adverse reactions. No treatment medication were provided.
Patient experienced slurred speech and difficulty with work finding. Dx by hospital with TIA. Resolution within 24-48 hours of onset.
Rather sudden onset of severe weakness of legs and unable to stand up from chair without assistance of wife or walker
Information was received on 13-JUN-2017 from a male patient of unknown age. No medical history or concomitant medications were reported. The patient reported that he received his first dose of GARDASIL 9 on 21-DEC-2016, his second dose on 07-FEB-2017 and his third dose on 20-APR-2017 (no lot numbers, expiration dates, dose or sites reported) for prophylaxis. The interval between the second and third dose was shorter than recommended. No adverse effects reported. No further information provided. Follow-up information was received on 14-JUN-2017 from the patient. He reported that he received the GARDASIL 9 vaccine injection at the age of 26 which is not indicated according to prescribing information. The patient did not experience any side effects from the injections. No further adverse experience information to report. Additional information is not expected. No permission to contact physician, no additional information to report.
VARIVAX was administered after undergoing a temperature excursion; This spontaneous report was received from a medical assistant and refers to a 12-month-old patient of unknown gender. Information regarding the patient's concomitant therapies, concurrent conditions, medical history and historical drugs was not provided.  On 19-JUL-2021, the patient was vaccinated with improperly stored varicella virus vaccine live (Oka/Merck) (VARIVAX) (dosage regimen was not reported), lot # T035400 and expiration date 16-OCT-2022 administered as prophylaxis.  The improperly stored dose of the suspect vaccine experienced a temperature excursion of 0.4 degree celsius (°C) for 13 hours and 10 minutes on an unspecified date; no previous temperature excursions were reported.   The call was made due to a digital data logger.   This is one of several cases received from the same reporter.; Sender's Comments:  US-009507513-2107USA006887: US-009507513-2107USA006957: US-009507513-2107USA007000: US-009507513-2107USA007004: US-009507513-2107USA007009:
This is a spontaneous report from a contactable pharmacist. A 65-year-old male patient received PREVNAR 13 (lot S51635, expiry date 31Oct2018, NDC number 00005197102) on 25Oct2017 at 10:52, at 0.5 ml single dose, intramuscular, in right upper arm, for pneumococcal prevention and the first dose of FLUZONE (lot UI882AA) on 25Oct2017, intramuscular, for immunization. Medical history included hypertension. Past drug history included muscle soreness after administration of the first dose of AFLURIA (lot WT51805, expiry date 24May2017) on an unspecified date in 2016, when he was 64 years old. Concomitant medications included unspecified drugs (reported as maintenance medications, he was not on any other injectable). The patient felt sore at injection site on 26Oct2017 but it went away by the next day. About a week later (on 02Nov2017 or 03Nov2017), he experienced muscle soreness in his right arm that spread over a couple of days down his right arm to his pinky and middle finger. He experienced this muscle soreness for 3 days and then it subsided; the patient recovered 95% from the muscle soreness. At the time of report he was experiencing tingling and numbness at the injection site which had developed on an unspecified date in 2017. There were no investigations. No emergency room or physician office visit were required. The reporting pharmacist considered that all the reported events were related to PREVNAR 13.
Early January I started to get really bad headaches, I went to the doctor on 2/25 around 5:30pm they ran a cat scan and found three blood clots. The doctor prescribed me to blood thinners and said I needed to take that for the next three months. Around the second week of taking the blood thinners I started to feel better but I am still on the blood thinners so it is still a ongoing issue.
1st shot just arm soreness and metal taste in mouth 2nd shot subconjuctival hemorrhage 6hrs post injection.  start of menstral cycle 9hrs post injection